Pharmagreen’s second formulation is currently under development, headed by
Ethan went on further to say, “My injuries were from a racing accident on motorcycles in 2009. And that accident was the main reason for playing with medicinal fungi. What led me to find these was the doctors told me I wouldn't fully heal in the locations that have a lot of cartilage due to lack of oxygen brought into the damaged area by blood flow. Cordyceps mushrooms add an extra oxygen molecule to the blood flow which in return sped up my healing by four to six months. All the bones in the wrists are in cartilage so healing them with screws, pins, and donor bones from a corpse is not an easy task.
A current hobby of Ethan's is sports car racing. The MaxGenomicTM racing team represented by Ethan (the designated driver) will be racing in ST4MASA Gran Turismo, NASA GR86 series. The racing team is focused on having fun and showcasing professional abilities. Come out and support the MaxGenomicTM racing team.
About
Pharmagreen is currently developing its nutraceutical products, and is focused on generating revenues from its proprietary blend of therapeutic plants and mushrooms, and nutraceutical wellness products. Utilizing the Company's expertise in plant genetics, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, and daily supplements with the potential to improve lives and address a wide variety of ailing conditions. For further information on the Company, and our website, please visit www.pharmagreen.ca
For company’s online store, please visit: www.maxgenomicproducts.com
Safe Harbor Statement
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.
Contact Information:
Tel: (702) 803 9404
Email: info@pharmagreen.ca
Corporate Website: www.pharmagreen.ca
Source:
2023 GlobeNewswire, Inc., source